{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:35:12Z","timestamp":1785414912755,"version":"3.56.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1124\/dmd.106.011288","type":"journal-article","created":{"date-parts":[[2006,12,2]],"date-time":"2006-12-02T01:44:33Z","timestamp":1165023873000},"page":"410-418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Effect of Oral Ketoconazole on Intestinal First-Pass Effect of Midazolam and Fexofenadine in Cynomolgus Monkeys"],"prefix":"10.1016","volume":"35","author":[{"given":"Akihito","family":"Ogasawara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Kume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Kazama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.106.011288_bib1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0009-9236(96)90163-0","article-title":"Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice","volume":"60","author":"Bailey","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.106.011288_bib2","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0090-9556(24)15235-X","article-title":"OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine","volume":"27","author":"Cvetkovic","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.011288_bib3","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm Res (NY)"},{"key":"10.1124\/dmd.106.011288_bib4","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/00912709922008515","article-title":"FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling","volume":"39","author":"Davit","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.106.011288_bib5","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1046\/j.1365-2125.2002.01591.x","article-title":"MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine","volume":"53","author":"Drescher","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.106.011288_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1067\/mcp.2002.121152","article-title":"Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine","volume":"71","author":"Dresser","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.106.011288_bib7","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.clpt.2004.10.005","article-title":"Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides","volume":"77","author":"Dresser","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.106.011288_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1067\/mcp.2003.10","article-title":"Coordinate induction of both cytochrome P4503A and MDR1 by St John\u2019s wort in healthy subjects","volume":"73","author":"Dresser","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.106.011288_bib9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1365-2125.1998.00679.x","article-title":"Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes","volume":"45","author":"Eagling","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.106.011288_bib10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0009-9236(97)90150-8","article-title":"Tacrolimus oral bioavailability doubles with coadministration of ketoconazole","volume":"62","author":"Floren","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.106.011288_bib11","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1124\/dmd.105.006874","article-title":"Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition","volume":"34","author":"Galetin","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.011288_bib12","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0090-9556(25)07487-2","article-title":"Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450","volume":"24","author":"Ghosal","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.011288_bib13","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0090-9556(24)15274-9","article-title":"Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of KI values and impact of CYP3A5 expression","volume":"27","author":"Gibbs","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.011288_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0009-9236(95)90067-5","article-title":"The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine","volume":"58","author":"Gomez","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.106.011288_bib15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0009-9236(98)90146-1","article-title":"The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin","volume":"64","author":"Gorski","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.106.011288_bib16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1067\/mcp.2001.113697","article-title":"The effect of rifampin administration on the disposition of fexofenadine","volume":"69","author":"Hamman","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.106.011288_bib17","first-page":"798","article-title":"A novel cytochrome P450 enzyme responsible for the metabolism of ebastine in monkey small intestine","volume":"29","author":"Hashizume","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.011288_bib18","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/jama.1993.03500120051025","article-title":"Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences","volume":"269","author":"Honig","year":"1993","journal-title":"J Am Med Assoc"},{"key":"10.1124\/dmd.106.011288_bib19","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1124\/dmd.104.000315","article-title":"Role of itraconazole metabolites in CYP3A4 inhibition","volume":"32","author":"Isoherranen","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.011288_bib20","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2133\/dmpk.20.206","article-title":"Glucuronidation of 2-(4-chlorophenyl)-5-(2-furyl)-4-oxazoleacetic acid (TA-1801A) in humans: species differences in liver and intestinal microsomes","volume":"20","author":"Kaji","year":"2005","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.106.011288_bib21","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/00498250500093786","article-title":"Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug-drug interaction model rats","volume":"35","author":"Kanazu","year":"2005","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.106.011288_bib22","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/00498250410001685755","article-title":"Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: Evaluation of cynomolgus monkeys as surrogates for humans","volume":"34","author":"Kanazu","year":"2004","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.106.011288_bib23","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2133\/dmpk.18.365","article-title":"The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature","volume":"18","author":"Kato","year":"2003","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.106.011288_bib24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/0091270004269705","article-title":"Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination","volume":"45","author":"Kharasch","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.106.011288_bib25","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1172\/JCI116064","article-title":"Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes","volume":"90","author":"Kolars","year":"1992","journal-title":"J Clin Investig"},{"key":"10.1124\/dmd.106.011288_bib26","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/0140-6736(91)92302-I","article-title":"First-pass metabolism of cyclosporine by the gut","volume":"338","author":"Kolars","year":"1991","journal-title":"Lancet"},{"key":"10.1124\/dmd.106.011288_bib27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0167-4781(92)90113-E","article-title":"Molecular cloning of monkey liver cytochrome P-450 cDNAs: similarity of the primary sequences to human cytochromes P-450","volume":"1171","author":"Komori","year":"1992","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/dmd.106.011288_bib28","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0009-9236(97)90027-8","article-title":"Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine","volume":"62","author":"Lown","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.106.011288_bib29","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1006\/abbi.1999.1506","article-title":"Molecular cloning, expression, and characterization of CYP2D17 from cynomolgus monkey liver","volume":"372","author":"Mankowski","year":"1999","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.106.011288_bib30","first-page":"271","article-title":"Serum binding of ketoconazole in health and disease","volume":"10","author":"Martinez-Jorda","year":"1990","journal-title":"Int J Clin Pharmacol Res"},{"key":"10.1124\/dmd.106.011288_bib31","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/gut.36.2.259","article-title":"Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues","volume":"36","author":"McKinnon","year":"1995","journal-title":"Gut"},{"key":"10.1124\/dmd.106.011288_bib32","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1124\/jpet.103.060194","article-title":"Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human","volume":"308","author":"Nozawa","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.106.011288_bib33","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1124\/jpet.105.093229","article-title":"The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions","volume":"316","author":"Obach","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.106.011288_bib34","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/clpt.1994.60","article-title":"Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole","volume":"55","author":"Olkkola","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.106.011288_bib35","first-page":"14","article-title":"First-pass metabolism of midazolam by the human intestine","volume":"60","author":"Paine","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.106.011288_bib36","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1067\/mcp.2002.128387","article-title":"Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin","volume":"72","author":"Paine","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.106.011288_bib37","first-page":"365","article-title":"Differential metabolism of midazolam in mouse liver and intestine microsomes: a comparison of cytochrome P450 activity and expression","volume":"33","author":"Perloff","year":"2003","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.106.011288_bib38","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1023\/B:PHAM.0000036913.90332.b1","article-title":"Transport characteristics of fexofenadine in the Caco-2 cell model","volume":"21","author":"Petri","year":"2004","journal-title":"Pharm Res (NY)"},{"key":"10.1124\/dmd.106.011288_bib39","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/00498250600571749","article-title":"Marked species differences in the bioavailability of midazolam in cynomolgus monkeys and humans","volume":"36","author":"Sakuda","year":"2006","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.106.011288_bib40","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1046\/j.1365-2125.1999.00999.x","article-title":"The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R\/S)-verapamil in humans","volume":"48","author":"Sandstr\u00f6m","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.106.011288_bib41","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","article-title":"Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians","volume":"270","author":"Shimada","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.106.011288_bib42","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1365-2125.2006.02613.x","article-title":"Effects of itraonazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein","volume":"61","author":"Shimizu","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.106.011288_bib43","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2165\/00003495-200059020-00020","article-title":"Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria","volume":"59","author":"Simpson","year":"2000","journal-title":"Drugs"},{"key":"10.1124\/dmd.106.011288_bib44","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJM200202143460721","article-title":"Cerivastatin and reports of fatal rhabdomyolysis","volume":"346","author":"Staffa","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.106.011288_bib45","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1124\/jpet.105.094052","article-title":"Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists","volume":"316","author":"Tahara","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.106.011288_bib46","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1124\/dmd.105.004192","article-title":"P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion","volume":"33","author":"Tahara","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.011288_bib47","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1046\/j.1365-2125.2003.01722.x","article-title":"The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique","volume":"55","author":"Tannergren","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.106.011288_bib48","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0009-9236(03)00238-8","article-title":"Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine","volume":"74","author":"Tannergren","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.106.011288_bib49","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0009-9236(96)90177-0","article-title":"Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism","volume":"59","author":"Thummel","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.106.011288_bib50","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0009-9236(99)70009-3","article-title":"Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole","volume":"66","author":"Tsunoda","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.106.011288_bib51","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/j.1552-4604.1996.tb04251.x","article-title":"Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents","volume":"36","author":"von Moltke","year":"1996","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.106.011288_bib52","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.clpt.2003.10.008","article-title":"Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens","volume":"75","author":"von Richter","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.106.011288_bib53","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1600-0773.1999.tb00085.x","article-title":"Midazolam \u03b1-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole","volume":"85","author":"Wang","year":"1999","journal-title":"Pharmacol Toxicol"},{"key":"10.1124\/dmd.106.011288_bib54","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1124\/dmd.32.2.259","article-title":"Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites","volume":"32","author":"Wang","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.011288_bib55","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1067\/mcp.2002.124080","article-title":"Effect of St. John\u2019s wort on the pharmacokinetics of fexofenadine","volume":"71","author":"Wang","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.106.011288_bib56","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1124\/dmd.32.6.603","article-title":"A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance","volume":"32","author":"Ward","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.011288_bib57","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1023\/A:1018906614320","article-title":"Inhibition of human CYP3A4 catalyzed 1\u2032-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine","volume":"11","author":"Wrighton","year":"1994","journal-title":"Pharm Res (NY)"},{"key":"10.1124\/dmd.106.011288_bib58","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1021\/mp050034j","article-title":"Comparison of species differences of P-glycoproteins in beagle dog, rhesus monkey, and human using ATPase activity assays","volume":"3","author":"Xia","year":"2006","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.106.011288_bib59","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/jpet.102.037549","article-title":"Interaction of cytochrome P450 3A inhibitors with P-glycoprotein","volume":"303","author":"Yasuda","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.106.011288_bib60","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clpt.2004.08.026","article-title":"Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics","volume":"77","author":"Yasui-Furukori","year":"2005","journal-title":"Clin Pharmacol Ther"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624012388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624012388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.106.011288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:27:33Z","timestamp":1739896053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624012388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S0090955624012388"],"URL":"https:\/\/doi.org\/10.1124\/dmd.106.011288","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Oral Ketoconazole on Intestinal First-Pass Effect of Midazolam and Fexofenadine in Cynomolgus Monkeys","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.106.011288","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2007 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}